126 related articles for article (PubMed ID: 37039670)
1. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Harigai M; Fujii T; Sakai R; Igarashi A; Shoji A; Yamaguchi H; Iwasaki K; Makishima M; Yoshida A; Okada N; Yamashita K; Kawahito Y
Mod Rheumatol; 2024 Feb; 34(2):287-296. PubMed ID: 37039670
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
3. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
4. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
5. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
[TBL] [Abstract][Full Text] [Related]
7. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
9. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Skovron ML; Frisell T; Askling J; Michaud K; Pedro S; Strangfeld A; Meissner Y; Boers M; Hoffman V; Dominique A; Gomez A; Hochberg MC
Semin Arthritis Rheum; 2024 Feb; 64():152313. PubMed ID: 38044241
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
Tarp S; Eric Furst D; Boers M; Luta G; Bliddal H; Tarp U; Heller Asmussen K; Brock B; Dossing A; Schjødt Jørgensen T; Thirstrup S; Christensen R
Rheumatology (Oxford); 2017 Mar; 56(3):417-425. PubMed ID: 28013201
[TBL] [Abstract][Full Text] [Related]
12. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
13. Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.
Kondo M; Yamada H
Mod Rheumatol; 2019 Nov; 29(6):928-935. PubMed ID: 30334661
[No Abstract] [Full Text] [Related]
14. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
15. Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data.
Takabayashi K; Ando F; Suzuki T
Mod Rheumatol; 2019 Jan; 29(1):87-97. PubMed ID: 29493381
[TBL] [Abstract][Full Text] [Related]
16. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
17. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data.
Kuwana M; Tamura N; Yasuda S; Fujio K; Shoji A; Yamaguchi H; Iwasaki K; Makishima M; Kawata Y; Yamashita K; Igarashi A
Mod Rheumatol; 2023 Mar; 33(2):302-311. PubMed ID: 35445720
[TBL] [Abstract][Full Text] [Related]
19. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Harigai M; Nanki T; Koike R; Tanaka M; Watanabe-Imai K; Komano Y; Sakai R; Yamazaki H; Koike T; Miyasaka N
Mod Rheumatol; 2016 Sep; 26(5):642-50. PubMed ID: 26873430
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
Gharaibeh M; Bonafede M; McMorrow D; Hernandez EJM; Stolshek BS
J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]